About Us

---

Cargin Enterprises is a privately held family office focused on long-term, disciplined investment in the life sciences sector. We partner with founders, researchers, and management teams developing next-generation biopharmaceutical therapies, with a particular emphasis on both early-stage innovation and later-stage clinical assets.

Our investment philosophy is grounded in a balance of scientific rigor and capital stewardship. We seek opportunities where strong underlying science intersects with clear paths to clinical and commercial viability. From preclinical platforms to advanced therapeutic programs, we take a thoughtful, selective approach—deploying capital where we believe we can support meaningful progress and durable value creation.

As a family office, we operate with a long-term perspective. We are not constrained by traditional fund cycles, allowing us to remain patient, flexible, and aligned with the development timelines inherent in the pharmaceutical landscape. This enables us to support our partners through critical inflection points—from early discovery through clinical development and beyond.

We value discretion, partnership, and disciplined execution. Our role extends beyond capital, serving as a steady and informed partner to teams navigating the complexities of drug development, regulatory pathways, and market positioning.

At Cargin Enterprises, we are committed to advancing innovation that has the potential to improve patient outcomes while generating sustainable, long-term returns.

CAGE Bio, currently a resident company at Johnson & Johnson Innovation JLBAS@ MBC BioLabs, is a clinical-stage startup exploiting its proprietary deep eutectic ionic liquid platform to develop novel products for dermatology, inflammation, and immunology.

Nanoscope Therapeutics is a clinical-stage biopharmaceutical company developing gene therapies to cure genetic diseases that cause vision impairment and blindness.

OncoNano Medicine is developing a new class of products that exploit universal cancer and immune therapeutic targets to diagnose and treat cancer. Our product candidates are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, agents for real-time image-guided surgery, and T cell activating immunotherapies.

Renibus Therapeutics is a biotech company dedicated to transforming the cardio-renal disease treatment paradigm by focusing on the prevention, treatment, and diagnostic testing of kidney disease. Each year, 9 million U.S. adults suffer from acute kidney injury (AKI), and today, 37 million U.S. adults are living with chronic kidney disease (CKD). As the most common complication of a number of surgical procedures, AKI occurs in approximately 30% of patients undergoing cardiac surgery. It is associated with a higher risk of mortality in both inpatient and outpatient settings, and progression to CKD within 24 months occurs in approximately 15-20% of patients who survive AKI.

Barricade Therapeutics is a privately held biotechnology company based in the Dallas–Fort Worth area focused on the development of first-in-class, targeted small molecule therapies for oncology. The company is advancing a novel class of compounds known as TASINs (Truncated APC Selective Inhibitors), designed to selectively target APC-mutant colorectal cancer—one of the most prevalent genetic drivers of the disease.

Secretome Therapeutics is a clinical-stage biotech company developing cell-free regenerative therapies based on the secretome of neonatal cardiac progenitor cells. Its platform targets tissue repair and inflammation modulation, with lead programs focused on heart failure and related conditions.